Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

Volume: 383, Issue: 11, Pages: 1040 - 1049
Published: Sep 9, 2020
Abstract
Background Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned...
Paper Details
Title
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Published Date
Sep 9, 2020
Volume
383
Issue
11
Pages
1040 - 1049
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.